GSK misses on late-stage CV drug

GSK misses on late-stage CV drug
GSK misses on late-stage CV drug

GlaxoSmithKline's atherosclerosis candidate darapladib missed its primary goal in a Phase III trial, the company reported today.  

The small-molecule drug is an inhibitor of Lp-PLA2, an enzyme associated with atherosclerotic plaque build-up. Results showed darapladib failed to reduce the relative risk of a stroke or heart attack by at least 6%, the trial's primary endpoint. The full results of the trial will be reported at a scientific meeting in 2014, GSK stated.

The news comes only a few weeks after the drugmaker announced sales slumped by 61% in China in the third quarter as a bribery probe continues in that country, and were flat overall at $10.6 billion for the quarter.

According to the Sanford Bernstein analyst Tim Anderson, darapladib and MAGE-A3—a cancer vaccine that also failed in a late-stage trial this past summer—offered potential upside in the drugmaker's pipeline for bullish investors.

Neither failure was a surprise, Anderson commented in a note to investors Tuesday, but they do raise bigger questions as to GSK's decision-making, specifically which programs it chooses to advance into Phase III.

"It has been a red flag that with both candidates, no other pharmaceutical companies were chasing the same dream," wrote Anderson. "If MAGE-A3 was a hot target then other cancer-focused pharma companies would have been pursuing the opportunity with their own products, but this was not the case. Similarly, with Lp-PLA2 inhibition (which is how darapladib works), if this was an exciting target then other cardiovascular-focused companies would [have] gone after this as well, and they did not."

While both drugs have disappointed thus far, GSK hasn't given up on the two potential treatments yet. Patrick Vallance, president of R&D at GSK, said in the statement, “Given the patient need in the area, we will continue to investigate the role of [darapladib] in coronary heart disease and other diseases.”

The company, which added that darapladib had been associated with “greater reductions” in “pre-determined secondary endpoints,” could not be reached for comment on which secondary endpoints those were. It did say it's working to better understand the data.

The experimental heart-disease treatment is being studied in another Phase III trial—SOLID-TIMI 52—which is measuring darapladib's effectiveness in patients who have already suffered an acute coronary event, to see if it can prevent the onset of a another attack. SOLID-TIMI 52 is slated to be complete in March 2014.

MAGE-A3's MAGRIT trial is currently underway to investigate the agent's effect in preventing cancer relapse after a tumor has been surgically removed.  

Anderson added that investors “will likely heavily discount both [products].”

GSK, though, has demonstrated it can deliver on its pipeline this year. In 2013 alone, it saw the approval of HIV/AIDS treatment dolutegravir,  COPD inhaler Breo, and an 11-2 recommendation from an FDA advisory panel for Anoro this past September.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions